SCHEMBL4826281

SCHEMBL4826281

NC1c2ccsc2N=CN1c1ccc(NC(=O)c2cccc(Cl)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.48
▸ NPC1 O15118 3/20 0.48
▸ KMT2A Q03164 4/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ KCNQ3 O43525 2/20 0.43
▸ KCNQ2 O43526 2/20 0.43
▸ KCNE1 P15382 2/20 0.43
▸ KCNQ1 P51787 2/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ MAPT P10636 3/20 0.43
▸ HTT P42858 1/20 0.43
▸ KCNQ5 Q9NR82 1/20 0.42
▸ KCNK3 O14649 1/20 0.41
▸ KCNK9 Q9NPC2 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ GCK P35557 1/20 0.41
▸ GRM5 P41594 1/20 0.41
▸ JAK2 O60674 1/20 0.41
▸ JAK1 P23458 1/20 0.41
▸ POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4835303 0.88 RAB9A (0.43) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL4831435 0.86 NPC1 (0.51) RAB9ANPC1KMT2AL3MBTL1MEN1
SCHEMBL4833679 0.86 GRM5 (0.47) L3MBTL1GRM5
SCHEMBL4825704 0.77 TRPV1 (0.48) KMT2AMEN1MAPTHTTSMN1; SMN2
SCHEMBL4833491 0.75 MAOA (0.49) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL4834612 0.74 BAZ1A (0.41) NPC1KMT2AKCNQ2MEN1MAPT
SCHEMBL4829077 0.74 NPY2R (0.43) KMT2AMEN1
SCHEMBL4829300 0.73 HDAC1 (0.43) RAB9ANPC1L3MBTL1MAPTKDM4E
SCHEMBL4825766 0.73 MAPK8 (0.47) RAB9AKMT2AMEN1POLBSMN1; SMN2
SCHEMBL4826378 0.72 CA12 (0.49) JAK2CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK RAB9A 3248/4885NPC1 4117/4885KMT2A 324/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR RAB9A 4166/4885NPC1 4782/4885KMT2A 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback